1. Home
  2. TVTX vs HIMS Comparison

TVTX vs HIMS Comparison

Compare TVTX & HIMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Travere Therapeutics Inc.

TVTX

Travere Therapeutics Inc.

HOLD

Current Price

$40.41

Market Cap

2.8B

Sector

Health Care

ML Signal

HOLD

Logo Hims & Hers Health Inc.

HIMS

Hims & Hers Health Inc.

HOLD

Current Price

$28.92

Market Cap

4.4B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
TVTX
HIMS
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Nursing Services
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
2.8B
4.4B
IPO Year
2013
2019

Fundamental Metrics

Financial Performance
Metric
TVTX
HIMS
Price
$40.41
$28.92
Analyst Decision
Strong Buy
Hold
Analyst Count
14
14
Target Price
$40.46
$29.50
AVG Volume (30 Days)
2.2M
23.2M
Earning Date
05-07-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
92.89
N/A
EPS
N/A
0.51
Revenue
N/A
$2,347,637,000.00
Revenue This Year
$43.88
$19.82
Revenue Next Year
$33.16
$19.23
P/E Ratio
N/A
$53.43
Revenue Growth
N/A
59.00
52 Week Low
$13.88
$13.74
52 Week High
$43.31
$70.43

Technical Indicators

Market Signals
Indicator
TVTX
HIMS
Relative Strength Index (RSI) 69.56 71.62
Support Level $32.62 $27.96
Resistance Level $41.44 $36.45
Average True Range (ATR) 2.17 1.70
MACD 1.26 0.91
Stochastic Oscillator 82.25 89.65

Price Performance

Historical Comparison
TVTX
HIMS

About TVTX Travere Therapeutics Inc.

Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease. It is also advancing pegtibatinase, a novel investigational enzyme replacement therapy for the treatment of HCU, a genetic disorder caused by a deficiency in a pivotal enzyme essential to the body.

About HIMS Hims & Hers Health Inc.

Hims & Hers, launched in 2017, is a telehealth platform that connects patients and healthcare providers to offer treatment options for specialties like erectile dysfunction, hair loss, skin care, mental health, and weight loss. Its offerings include generic, branded, and compounded prescription drugs as well as over-the-counter medicines, cosmetics, and supplements. The platform, which has more than 2 million subscribers, is available in all 50 states and certain European markets like the UK. It includes provider networks, electronic medical records, cloud pharmacy fulfillment, and personalization capabilities. Hims does not take insurance and only accepts payments directly from customers.

Share on Social Networks: